home / stock / vxrt / vxrt news

VXRT News and Press, Vaxart Inc.

Stock Information
Company Name: Vaxart Inc.
Stock Symbol: VXRT
Market: NASDAQ
Website: vaxart.com
Menu
VXRT VXRT Quote VXRT Short VXRT News VXRT Articles VXRT Message Board
Get VXRT Alerts

News, Short Squeeze, Breakout and More Instantly...
VXRT - Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced that members of the management team will present at the Oppenheimer 36t...
VXRT - Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants

Vaccine was safe and well-tolerated and led to a significant increase in norovirus-specific antibodies in serum and breast milk Norovirus-specific IgA in infant stool correlated with breast milk IgA, suggesting passive transfer of immunity to breastfed infants and the potential for a new appr...

VXRT - Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026

SOUTH SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart or “the Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will p...

VXRT - Vaxart, Inc. (VXRT) Shareholder/Analyst Call Transcript

2025-11-18 21:28:47 ET Vaxart, Inc. (VXRT) Shareholder/Analyst Call November 18, 2025 4:30 PM EST Company Participants Steven Lo - President, CEO & Director Jeroen Grasman - CFO, Principal Accounting Officer & Principal Financial Officer Edward Berg - Senio...
VXRT - Vaxart, Precigen among biotech gainers after Q3 results

2025-11-14 14:06:21 ET More on Vaxart, Precigen Precigen, Inc. (PGEN) Q3 2025 Earnings Call Transcript Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript The Outlook For Precigen Vaxart extends cash runway into Q2 2027 with Dynavax partnership and targets 2...

VXRT - Vaxart extends cash runway into Q2 2027 with Dynavax partnership and targets 2026 data readouts

2025-11-13 22:42:16 ET More on Vaxart Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript Vaxart, Inc. (VXRT) Presents at H.C. Wainwright 27th Annual Global Investment Conference - Slideshow Seeking Alpha’s Quant Rating on Vaxart Historical earnings d...

VXRT - Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript

2025-11-13 22:41:34 ET Vaxart, Inc. (VXRT) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Edward Berg - Senior VP & General Counsel Steven Lo - President, CEO & Director James Cummings - Chief Medical Officer Sean Tucker - Se...
VXRT - Vaxart GAAP EPS of -$0.04 beats by $0.03, revenue of $72.4M beats by $32.3M

2025-11-13 16:08:43 ET More on Vaxart Vaxart, Inc. (VXRT) Presents at H.C. Wainwright 27th Annual Global Investment Conference - Slideshow Seeking Alpha’s Quant Rating on Vaxart Historical earnings data for Vaxart Financial information for Vaxart ...

VXRT - Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results

Entered into an exclusive license agreement with Dynavax for the Company’s COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment of approximately 5,400 participants in COVID-19 Phase 2b trial with topline da...

VXRT - Here are the major earnings after the close Thursday

2025-11-13 10:00:00 ET Read the full article on Seeking Alpha For further details see: Here are the major earnings after the close Thursday
Next 10